Free Trial

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.8%

Arrowhead Pharmaceuticals logo with Medical background

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) was down 4.8% on Monday . The stock traded as low as $24.59 and last traded at $24.61. Approximately 199,568 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,325,535 shares. The stock had previously closed at $25.84.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ARWR shares. Morgan Stanley decreased their target price on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an "equal weight" rating on the stock in a research report on Monday, May 13th. HC Wainwright restated a "buy" rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They issued a "neutral" rating and a $31.00 target price on the stock. Finally, Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $47.89.

View Our Latest Report on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Stock Down 2.9 %

The company has a market cap of $3.12 billion, a PE ratio of -5.91 and a beta of 0.94. The stock has a 50-day simple moving average of $24.20 and a 200 day simple moving average of $28.28.


Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period in the previous year, the company posted $0.45 earnings per share. The firm's revenue was down 100.0% compared to the same quarter last year. As a group, research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the sale, the director now owns 30,205 shares in the company, valued at $704,078.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Hongbo Lu acquired 1,000 shares of the company's stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average cost of $27.50 per share, with a total value of $27,500.00. Following the completion of the purchase, the director now owns 33,680 shares of the company's stock, valued at approximately $926,200. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares of the company's stock, valued at $704,078.55. The disclosure for this sale can be found here. Company insiders own 4.50% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the first quarter valued at $269,000. Comerica Bank grew its stake in Arrowhead Pharmaceuticals by 11.2% during the 1st quarter. Comerica Bank now owns 48,312 shares of the biotechnology company's stock worth $1,382,000 after purchasing an additional 4,855 shares in the last quarter. California State Teachers Retirement System grew its stake in Arrowhead Pharmaceuticals by 14.1% during the 1st quarter. California State Teachers Retirement System now owns 122,486 shares of the biotechnology company's stock worth $3,503,000 after purchasing an additional 15,136 shares in the last quarter. Janus Henderson Group PLC grew its stake in Arrowhead Pharmaceuticals by 21.3% during the 1st quarter. Janus Henderson Group PLC now owns 57,449 shares of the biotechnology company's stock worth $1,641,000 after purchasing an additional 10,082 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $724,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

See Also

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

CPI News Breakdown: Key Market Moves to Follow

CPI News Breakdown: Key Market Moves to Follow

Join us as we break down the latest CPI news, its effect on your favorite stocks, and the broader market. We also discuss how these economic indicators might lead to a potential interest rate cut by t

Related Videos

Inside Pelosi’s Latest Stock Moves
4 Best Tech Stocks to Own in 2024
NVIDIA Tops Microsoft and Apple for Most Valuable Company

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines